180 related articles for article (PubMed ID: 7985028)
21. Cytoplasmic tail-dependent localization of CD1b antigen-presenting molecules to MIICs.
Sugita M; Jackman RM; van Donselaar E; Behar SM; Rogers RA; Peters PJ; Brenner MB; Porcelli SA
Science; 1996 Jul; 273(5273):349-52. PubMed ID: 8662520
[TBL] [Abstract][Full Text] [Related]
22. Separation of subcellular compartments containing distinct functional forms of MHC class II.
Qiu Y; Xu X; Wandinger-Ness A; Dalke DP; Pierce SK
J Cell Biol; 1994 May; 125(3):595-605. PubMed ID: 7909813
[TBL] [Abstract][Full Text] [Related]
23. Developing and shedding inhibitions: how MHC class II molecules reach maturity.
Busch R; Mellins ED
Curr Opin Immunol; 1996 Feb; 8(1):51-8. PubMed ID: 8729446
[TBL] [Abstract][Full Text] [Related]
24. A mutant human histocompatibility leukocyte antigen DR molecule associated with invariant chain peptides.
Mellins E; Cameron P; Amaya M; Goodman S; Pious D; Smith L; Arp B
J Exp Med; 1994 Feb; 179(2):541-9. PubMed ID: 8294865
[TBL] [Abstract][Full Text] [Related]
25. Presentation of endogenously synthesized MHC class II-restricted epitopes by MHC class II cancer vaccines is independent of transporter associated with Ag processing and the proteasome.
Dissanayake SK; Tuera N; Ostrand-Rosenberg S
J Immunol; 2005 Feb; 174(4):1811-9. PubMed ID: 15699107
[TBL] [Abstract][Full Text] [Related]
26. Efficient internalization of MHC class II-invariant chain complexes is not sufficient for invariant chain proteolysis and class II antigen presentation.
Swier K; Miller J
J Immunol; 1995 Jul; 155(2):630-43. PubMed ID: 7608541
[TBL] [Abstract][Full Text] [Related]
27. Evidence for invariant chain 85-101 (CLIP) binding in the antigen binding site of MHC class II molecules.
Bangia N; Watts TH
Int Immunol; 1995 Oct; 7(10):1585-91. PubMed ID: 8562503
[TBL] [Abstract][Full Text] [Related]
28. The pathway for MHCII-mediated presentation of endogenous proteins involves peptide transport to the endo-lysosomal compartment.
Dani A; Chaudhry A; Mukherjee P; Rajagopal D; Bhatia S; George A; Bal V; Rath S; Mayor S
J Cell Sci; 2004 Aug; 117(Pt 18):4219-30. PubMed ID: 15316082
[TBL] [Abstract][Full Text] [Related]
29. A defective viral superantigen-presenting phenotype in HLA-DR transfectants is corrected by CIITA.
Azar GA; Sékaly RP; Thibodeau J
J Immunol; 2005 Jun; 174(12):7548-57. PubMed ID: 15944254
[TBL] [Abstract][Full Text] [Related]
30. Downmodulation of antigen presentation by H2-O in B cell lines and primary B lymphocytes.
Brocke P; Armandola E; Garbi N; Hämmerling GJ
Eur J Immunol; 2003 Feb; 33(2):411-21. PubMed ID: 12645938
[TBL] [Abstract][Full Text] [Related]
31. Invariant chain modulates HLA class II protein recycling and peptide presentation in nonprofessional antigen presenting cells.
Haque A; Hajiaghamohseni LM; Li P; Toomy K; Blum JS
Cell Immunol; 2007 Sep; 249(1):20-9. PubMed ID: 18067883
[TBL] [Abstract][Full Text] [Related]
32. The requirement for DM in class II-restricted antigen presentation and SDS-stable dimer formation is allele and species dependent.
Stebbins CC; Loss GE; Elias CG; Chervonsky A; Sant AJ
J Exp Med; 1995 Jan; 181(1):223-34. PubMed ID: 7807005
[TBL] [Abstract][Full Text] [Related]
33. Altered antigen presentation in mice lacking H2-O.
Liljedahl M; Winqvist O; Surh CD; Wong P; Ngo K; Teyton L; Peterson PA; Brunmark A; Rudensky AY; Fung-Leung WP; Karlsson L
Immunity; 1998 Feb; 8(2):233-43. PubMed ID: 9492004
[TBL] [Abstract][Full Text] [Related]
34. Major histocompatibility complex class II compartments in human B lymphoblastoid cells are distinct from early endosomes.
Peters PJ; Raposo G; Neefjes JJ; Oorschot V; Leijendekker RL; Geuze HJ; Ploegh HL
J Exp Med; 1995 Aug; 182(2):325-34. PubMed ID: 7629497
[TBL] [Abstract][Full Text] [Related]
35. Effect of HLA-DM transfection on hen egg lysozyme presentation by T2.Ak cells.
Albert LJ; Ghumman B; Watts TH
J Immunol; 1996 Sep; 157(6):2247-55. PubMed ID: 8805621
[TBL] [Abstract][Full Text] [Related]
36. Endosomal localization of MHC class II-invariant chain complexes.
Miller J
Immunol Res; 1994; 13(4):244-52. PubMed ID: 7616052
[TBL] [Abstract][Full Text] [Related]
37. Quality control of MHC class II associated peptides by HLA-DM/H2-M.
Vogt AB; Arndt SO; Hämmerling GJ; Kropshofer H
Semin Immunol; 1999 Dec; 11(6):391-403. PubMed ID: 10625593
[TBL] [Abstract][Full Text] [Related]
38. Invariant chain-independent function of H-2M in the formation of endogenous peptide-major histocompatibility complex class II complexes in vivo.
Kovats S; Grubin CE; Eastman S; deRoos P; Dongre A; Van Kaer L; Rudensky AY
J Exp Med; 1998 Jan; 187(2):245-51. PubMed ID: 9432982
[TBL] [Abstract][Full Text] [Related]
39. Impaired antigen presentation by murine I-Ad class II MHC molecules expressed in normal and HLA-DM-defective human B cell lines.
Weenink S; Averdunk H; Boston T; Boswarva V; Guery JC; Adorini L; Mellins E; McCluskey J; Gautam AM
Int Immunol; 1997 Jun; 9(6):889-96. PubMed ID: 9199972
[TBL] [Abstract][Full Text] [Related]
40. Hydrogen bond integrity between MHC class II molecules and bound peptide determines the intracellular fate of MHC class II molecules.
Arneson LS; Katz JF; Liu M; Sant AJ
J Immunol; 2001 Dec; 167(12):6939-46. PubMed ID: 11739513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
